COVID-19：US Eli Lily，Corona抗体药物：临床试验中住院率下降
美国制药Eli Lily：
9月16日，Eli Lily宣布了一项正在研发的新型冠状病毒抗体药物的中期临床试验结果。
抗体药物的给药：
抗体药物的使用降低了轻度至中度新电晕患者的住院率。
Eli Lily还在8月开始了一项后期临床试验。
中期临床试验：
在约450名新的电晕患者中进行了中期临床试验。
施用了不同剂量的抗体药物。
试验结果：
结果，总体上，接受抗体药物的患者的住院率低于接受安慰剂（假冒药物）的患者的住院率。
此外，接受中剂量抗体药物的患者的病毒量明显低于低剂量和高剂量的患者。
中期试验正在进行中，计划于10月至12月完成。
抗体药物“ LY-CoV555”
Lily的单克隆抗体药物“ LY-CoV555”与加拿大Abcelera Biologics共同开发。
从新电晕恢复患者中提取的抗体是模型。
通过防止新的日冕病毒入侵人类细胞，
有望有效预防感染和加重。
日本经济新闻
https://www.nikkei.com/article/DGXMZO63947180X10C20A9000000/
Lilly’s LY-CoV555 Shows Promise Targeting COVID-19 With Phase 2 Interim Analysis
Eli Lilly and Company (NYSE: LLY)
announced that proof of concept data from an interim analysis of the BLAZE-1 clinical trial reveals a reduced rate of hospitalization for patients treated with LY-CoV555.
LY-CoV555
An ongoing randomized,
double-blind,
placebo-controlled Phase 2 studyreveals centers on the investigational product known as LY-CoV555.
AbCellera
Developed thanks to a partnership
affording access to powerful drug discovery technology from AbCellera,in combination with dedicated Lilly scientists working day and night starting back in the early Spring,
this potent monoclonal antibody demonstrates real promise as a regimen targeting both COVID-19 prevention and treatment.
Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19
TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization
was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program.
also selected by Eli Lilly
Now, local media (WSYX/WTTE)
reports that the Columbus-based site was also selected by Eli Lilly for participation in the BLAZE-1 study investigating advanced monoclonal antibodies targeting COVID-19.LY-CoV555 and LY-CoV016,
This particular study involves LY-CoV555 and LY-CoV016, one of which originated out of a collaboration between Lilly and AbCellera (March) and the other a license deal with Junshi Biosciences in China (May).
Dr. Samir Arora
founded Aventiv Research back in 2007; the Columbus principal investigator recently expressed his excitement about this antibody treatment under investigationemphasizing to local Columbus media that if this particular treatment proves successful in clinical trials, it would be one of the first medications on the market to help patients fight off COVID-19.